Advances in Targeted Therapy of Non-small Cell Lung Cancer with EGFR Combined With P53 Gene Mutation
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i2.2316
Abstract
Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer death worldwide. NSCLC patients with epidermal growth factor receptor (EGFR) mutations were treated with EGFR-tyrosine kinase inhibitor (TKI), but EGFR mutations combined with other genes had a shorter survival. However, the P53 gene mutation is a common combined mutation in patients with NSCLC with EGFR gene mutation. This review summarizes the development of targeted NSCLC for EGFR with P53 mutations.
Keywords
non-small cell lung cancer; epidermal growth factor receptor; P53 gene
Funding
High level Talent Research Project of the Affiliated Hospital of Youjiang Medical University For Nationalities (20212601);Project of Baise City Science Research and Technology Development Program (202241062022)
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1]Wu Ning, Cheng Guanghui, Han Dongmei, et al. Experimental study of two-component targeted adenovirus vector targeting EGFR to mediate wild-type p53 and endostatin dual gene combined radiotherapy in non-small cell lung cancer [C]. 2016:518-518.
[2]Passaro A, Attili I, Rappa A, et al. Genomic characterization of concurrent alterations in non-small cell lung cancer (NSCLC) harboring actionable mutations[J]. Cancers (Basel), 2021, 13(9): 2172.
[3]Vaughan CA, Pearsall I, Singh S, et al. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter[J]. Oncotarget, 2016, 7(11): 12426-12446.
[4]Wang W, Cheng B, Miao L, et al. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression [J]. Cell Death Dis, 2013, 4(4): e574.
[5]Zhang C, Liu J, Xu D, et al. Gain-of-function mutant p53 in cancer progression and therapy [J]. J Mol Cell Biol, 2020, 12(9): 674-687.
[6]Dong P, Xu Z, Jia N, et al. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway[J]. Mol Cancer, 2009, 8: 103
[7]Lakoduk AM, Roudot P, Mettlen M, et al. Mutant p53 amplifies a dynamin-1/APPL1 endosome feedback loop that regulates recycling and migration[J]. J Cell Biol, 2019, 218 (6): 1928-1942
[8]Vokes NI, Chambers E, Nguyen T, et al. Concurrent P53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J]. J Thorac Oncol, 2022, 17(6): 779-792.
[9]CANALEM, PETRACCI E, DELMONTE A.et al. ConcomitantP53mutationconfers worse prognosisin EGFRmutated non-small cell lung cancer patients treated with TKIs [J],J Clin Med,2020,9(4):1047.
[10]FUYL.WANGAQ.ZHOUJQ: et al. Advanced NSCLC patientswith EGFRT790M harboringP53R273Cor KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquidbiopsy[J.FrontOncol 2021.11:621992.
[11]NAKAGAWAK,NADALEGARONEB.et al. RELAY subgroup analyses byEGFR Exl9del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic nonsmall cell lung cancer[J].ClinCancerRes2021.27（19）:5258- 5271
[12] Zhang Chi, Shi Qingming, Gu Kangsheng. Clinical efficacy and safety of cream-directed + chemotherapy in elderly patients with EGFR + P53 [J]. Chinese Journal of Gerontology, 2022.42 (8): 1830-1832.
[13]WIESTN,MAJEEDU,SEEGOBINK.etal.Role of immune checkpoint inhibitor therapy in advanced EGFR-mutant non small cell lung cancer[J]. Front Oncol.2021.11:751209.
[2]Passaro A, Attili I, Rappa A, et al. Genomic characterization of concurrent alterations in non-small cell lung cancer (NSCLC) harboring actionable mutations[J]. Cancers (Basel), 2021, 13(9): 2172.
[3]Vaughan CA, Pearsall I, Singh S, et al. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter[J]. Oncotarget, 2016, 7(11): 12426-12446.
[4]Wang W, Cheng B, Miao L, et al. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression [J]. Cell Death Dis, 2013, 4(4): e574.
[5]Zhang C, Liu J, Xu D, et al. Gain-of-function mutant p53 in cancer progression and therapy [J]. J Mol Cell Biol, 2020, 12(9): 674-687.
[6]Dong P, Xu Z, Jia N, et al. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway[J]. Mol Cancer, 2009, 8: 103
[7]Lakoduk AM, Roudot P, Mettlen M, et al. Mutant p53 amplifies a dynamin-1/APPL1 endosome feedback loop that regulates recycling and migration[J]. J Cell Biol, 2019, 218 (6): 1928-1942
[8]Vokes NI, Chambers E, Nguyen T, et al. Concurrent P53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J]. J Thorac Oncol, 2022, 17(6): 779-792.
[9]CANALEM, PETRACCI E, DELMONTE A.et al. ConcomitantP53mutationconfers worse prognosisin EGFRmutated non-small cell lung cancer patients treated with TKIs [J],J Clin Med,2020,9(4):1047.
[10]FUYL.WANGAQ.ZHOUJQ: et al. Advanced NSCLC patientswith EGFRT790M harboringP53R273Cor KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquidbiopsy[J.FrontOncol 2021.11:621992.
[11]NAKAGAWAK,NADALEGARONEB.et al. RELAY subgroup analyses byEGFR Exl9del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic nonsmall cell lung cancer[J].ClinCancerRes2021.27（19）:5258- 5271
[12] Zhang Chi, Shi Qingming, Gu Kangsheng. Clinical efficacy and safety of cream-directed + chemotherapy in elderly patients with EGFR + P53 [J]. Chinese Journal of Gerontology, 2022.42 (8): 1830-1832.
[13]WIESTN,MAJEEDU,SEEGOBINK.etal.Role of immune checkpoint inhibitor therapy in advanced EGFR-mutant non small cell lung cancer[J]. Front Oncol.2021.11:751209.
Copyright © 2024 Di Lu, Yueyong Li, Ju Liao, Wenxian Lin, Xiuli Mao, Xinxin Wei, Xiaohong Qin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License